Literature DB >> 29246098

Optic Pathway Gliomas in Neurofibromatosis Type 1.

Cynthia J Campen1, David H Gutmann2.   

Abstract

Neurofibromatosis type 1 (NF1) is one of the most common brain tumor predisposition syndromes, in which affected children are prone to the development of low-grade gliomas. While NF1-associated gliomas can be found in several brain regions, the majority arise in the optic nerves, chiasm, tracts, and radiations (optic pathway gliomas; OPGs). Owing to their location, 35-50% of affected children present with reduced visual acuity. Unfortunately, despite tumor stabilization following chemotherapy, vision does not improve in most children. For this reasons, more effective therapies are being sought that reflect a deeper understanding of the NF1 gene and the use of authenticated Nf1 genetically-engineered mouse strains. The implementation of these models for drug discovery and validation has galvanized molecularly-targeted clinical trials in children with NF1-OPG. Future research focused on defining the cellular and molecular factors that underlie optic glioma development and progression also has the potential to provide personalized risk assessment strategies for this pediatric population.

Entities:  

Keywords:  RAS; astrocytoma; low-grade glioma; pilocytic; precision medicine; vision

Mesh:

Year:  2018        PMID: 29246098      PMCID: PMC5739070          DOI: 10.1177/0883073817739509

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  81 in total

1.  Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

Authors:  Eric Bouffet; Regina Jakacki; Stewart Goldman; Darren Hargrave; Cynthia Hawkins; Manohar Shroff; Juliette Hukin; Ute Bartels; Nicholas Foreman; Stewart Kellie; Joanne Hilden; Michael Etzl; Beverly Wilson; Derek Stephens; Uri Tabori; Sylvain Baruchel
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

2.  Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1.

Authors:  Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson
Journal:  J Pediatr       Date:  2015-05-28       Impact factor: 4.406

3.  Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo.

Authors:  Debasish Banerjee; Balazs Hegedus; David H Gutmann; Joel R Garbow
Journal:  Neuroimage       Date:  2007-02-23       Impact factor: 6.556

4.  Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.

Authors:  Yuan Zhu; Takayuki Harada; Li Liu; Mark E Lush; Frantz Guignard; Chikako Harada; Dennis K Burns; M Livia Bajenaru; David H Gutmann; Luis F Parada
Journal:  Development       Date:  2005-12       Impact factor: 6.868

Review 5.  Late-onset optic pathway tumors in children with neurofibromatosis 1.

Authors:  R Listernick; R E Ferner; L Piersall; S Sharif; D H Gutmann; J Charrow
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

6.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

Review 7.  Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research.

Authors:  Robert A Avery; Rosalie E Ferner; Robert Listernick; Michael J Fisher; David H Gutmann; Grant T Liu
Journal:  J Neurooncol       Date:  2012-07-28       Impact factor: 4.130

8.  Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

Authors:  D H Gutmann; S A Rasmussen; P Wolkenstein; M M MacCollin; A Guha; P D Inskip; K N North; M Poyhonen; P H Birch; J M Friedman
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

9.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

10.  Precocious puberty in children with neurofibromatosis type 1.

Authors:  R Habiby; B Silverman; R Listernick; J Charrow
Journal:  J Pediatr       Date:  1995-03       Impact factor: 4.406

View more
  35 in total

1.  Inflaming glioma growth.

Authors:  Marlene Arzt; Michelle Monje
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

2.  Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.

Authors:  Xiaofan Guo; Yuan Pan; David H Gutmann
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

3.  Long-term visual acuity outcomes after radiation therapy for sporadic optic pathway glioma.

Authors:  Sahaja Acharya; Sophia Quesada; Kenneth Coca; Cody Richardson; Mary E Hoehn; Jason Chiang; Ibrahim Qaddoumi; Frederick A Boop; Amar Gajjar; Thomas E Merchant
Journal:  J Neurooncol       Date:  2019-08-14       Impact factor: 4.130

4.  68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma.

Authors:  Jingjing Zhang; Yongji Tian; Deling Li; Gang Niu; Lixin Lang; Fang Li; Yuhan Liu; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-03       Impact factor: 9.236

5.  Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.

Authors:  Chelsea Kotch; Robert Avery; Kelly D Getz; Eric Bouffet; Peter de Blank; Robert Listernick; David H Gutmann; Miriam Bornhorst; Cynthia Campen; Grant T Liu; Richard Aplenc; Yimei Li; Michael J Fisher
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

Review 6.  Molecular alterations of low-grade gliomas in young patients: Strategies and platforms for routine evaluation.

Authors:  Iman Dandapath; Rituparna Chakraborty; Kavneet Kaur; Swati Mahajan; Jyotsna Singh; Mehar C Sharma; Chitra Sarkar; Vaishali Suri
Journal:  Neurooncol Pract       Date:  2021-08-23

Review 7.  Visual function tests including the role of optical coherence tomography in neurofibromatosis 1.

Authors:  Daphna Mezad-Koursh; Anat Bachar Zipori; Dinah Zur; Lior Degabli; Meital Ben-Dov; Ainat Klein
Journal:  Childs Nerv Syst       Date:  2020-08-04       Impact factor: 1.475

Review 8.  Neurosurgical experience of managing optic pathway gliomas.

Authors:  Ciaran Scott Hill; Mehdi Khan; Kim Phipps; Katherine Green; Darren Hargrave; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2021-02-03       Impact factor: 1.475

Review 9.  Radiohistogenomics of pediatric low-grade neuroepithelial tumors.

Authors:  Asim K Bag; Jason Chiang; Zoltan Patay
Journal:  Neuroradiology       Date:  2021-03-29       Impact factor: 2.804

10.  Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins.

Authors:  Juan Mo; Corina Anastasaki; Zhiguo Chen; Tracey Shipman; Jason Papke; Kevin Yin; David H Gutmann; Lu Q Le
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.